Enrollment complete in second BPH Phase 3 trial

|By:, SA News Editor

Patient enrollment is complete in Nymox Pharmaceuticals' (NYMX -0.4%) second re-injection Phase 3 clinical trial evaluating the safety and efficacy on NX-1207 as a treatment of enlarged prostate or benign prostatic hyperplasia (BPH). In the first re-injection study, patients demonstrated a mean symptomatic improvement in the AUA BPH Symptom Score of 7.6 points.

NX-1207 is administered by injection directly into the prostate gland. It is currently being assessed in five Phase 3 trials and one Phase 2 trial.